429 related articles for article (PubMed ID: 30219886)
21. Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Bines J; Procter M; Restuccia E; Viale G; Zardavas D; Suter T; Arahmani A; Van Dooren V; Baselga J; Clark E; Eng-Wong J; Gelber RD; Piccart M; Mobus V; de Azambuja E;
Clin Breast Cancer; 2020 Apr; 20(2):174-181.e3. PubMed ID: 31924513
[TBL] [Abstract][Full Text] [Related]
22. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
Cameron D; Piccart-Gebhart MJ; Gelber RD; Procter M; Goldhirsch A; de Azambuja E; Castro G; Untch M; Smith I; Gianni L; Baselga J; Al-Sakaff N; Lauer S; McFadden E; Leyland-Jones B; Bell R; Dowsett M; Jackisch C;
Lancet; 2017 Mar; 389(10075):1195-1205. PubMed ID: 28215665
[TBL] [Abstract][Full Text] [Related]
23. Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial.
Joensuu H; Fraser J; Wildiers H; Huovinen R; Auvinen P; Utriainen M; Nyandoto P; Villman KK; Halonen P; Granstam-Björneklett H; Lundgren L; Sailas L; Turpeenniemi-Hujanen T; Tanner M; Yachnin J; Ritchie D; Johansson O; Huttunen T; Neven P; Canney P; Harvey VJ; Kellokumpu-Lehtinen PL; Lindman H
JAMA Oncol; 2018 Sep; 4(9):1199-1206. PubMed ID: 29852043
[TBL] [Abstract][Full Text] [Related]
24. Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99.
Pagani O; Klingbiel D; Ruhstaller T; Nolè F; Eppenberger S; Oehlschlegel C; Bernhard J; Brauchli P; Hess D; Mamot C; Munzone E; Pestalozzi B; Rabaglio M; Aebi S; Ribi K; Rochlitz C; Rothgiesser K; Thürlimann B; von Moos R; Zaman K; Goldhirsch A;
Ann Oncol; 2017 Feb; 28(2):305-312. PubMed ID: 27998961
[TBL] [Abstract][Full Text] [Related]
25. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
van Ramshorst MS; van Werkhoven E; Honkoop AH; Dezentjé VO; Oving IM; Mandjes IA; Kemper I; Smorenburg CH; Stouthard JM; Linn SC; Sonke GS;
Breast; 2016 Oct; 29():153-9. PubMed ID: 27498129
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trial.
Papakonstantinou A; Matikas A; Bengtsson NO; Malmström P; Hedayati E; Steger G; Untch M; Hübbert L; Johansson H; Hellström M; Gnant M; Loibl S; Greil R; Moebus V; Foukakis T; Bergh J
Cancer; 2020 Mar; 126(6):1175-1182. PubMed ID: 31851385
[TBL] [Abstract][Full Text] [Related]
27. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Diéras V; Miles D; Verma S; Pegram M; Welslau M; Baselga J; Krop IE; Blackwell K; Hoersch S; Xu J; Green M; Gianni L
Lancet Oncol; 2017 Jun; 18(6):732-742. PubMed ID: 28526536
[TBL] [Abstract][Full Text] [Related]
28. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.
Harbeck N; Huang CS; Hurvitz S; Yeh DC; Shao Z; Im SA; Jung KH; Shen K; Ro J; Jassem J; Zhang Q; Im YH; Wojtukiewicz M; Sun Q; Chen SC; Goeldner RG; Uttenreuther-Fischer M; Xu B; Piccart-Gebhart M;
Lancet Oncol; 2016 Mar; 17(3):357-366. PubMed ID: 26822398
[TBL] [Abstract][Full Text] [Related]
29. Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).
Mavroudis D; Matikas A; Malamos N; Papakotoulas P; Kakolyris S; Boukovinas I; Athanasiadis A; Kentepozidis N; Ziras N; Katsaounis P; Saloustros E; Georgoulias V;
Ann Oncol; 2016 Oct; 27(10):1873-8. PubMed ID: 27502729
[TBL] [Abstract][Full Text] [Related]
30. Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients.
Watanuki R; Hayashida T; Kawai Y; Kikuchi M; Nakashoji A; Yokoe T; Toyota T; Seki T; Takahashi M; Kitagawa Y
Int J Clin Oncol; 2019 Jul; 24(7):807-814. PubMed ID: 30810890
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
van Ramshorst MS; van der Voort A; van Werkhoven ED; Mandjes IA; Kemper I; Dezentjé VO; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS;
Lancet Oncol; 2018 Dec; 19(12):1630-1640. PubMed ID: 30413379
[TBL] [Abstract][Full Text] [Related]
32. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
Gelmon KA; Boyle FM; Kaufman B; Huntsman DG; Manikhas A; Di Leo A; Martin M; Schwartzberg LS; Lemieux J; Aparicio S; Shepherd LE; Dent S; Ellard SL; Tonkin K; Pritchard KI; Whelan TJ; Nomikos D; Nusch A; Coleman RE; Mukai H; Tjulandin S; Khasanov R; Rizel S; Connor AP; Santillana SL; Chapman JA; Parulekar WR
J Clin Oncol; 2015 May; 33(14):1574-83. PubMed ID: 25779558
[TBL] [Abstract][Full Text] [Related]
33. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer.
Perez EA; Suman VJ; Davidson NE; Gralow JR; Kaufman PA; Visscher DW; Chen B; Ingle JN; Dakhil SR; Zujewski J; Moreno-Aspitia A; Pisansky TM; Jenkins RB
J Clin Oncol; 2011 Dec; 29(34):4491-7. PubMed ID: 22042958
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.
Piccart-Gebhart M; Holmes E; Baselga J; de Azambuja E; Dueck AC; Viale G; Zujewski JA; Goldhirsch A; Armour A; Pritchard KI; McCullough AE; Dolci S; McFadden E; Holmes AP; Tonghua L; Eidtmann H; Dinh P; Di Cosimo S; Harbeck N; Tjulandin S; Im YH; Huang CS; Diéras V; Hillman DW; Wolff AC; Jackisch C; Lang I; Untch M; Smith I; Boyle F; Xu B; Gomez H; Suter T; Gelber RD; Perez EA
J Clin Oncol; 2016 Apr; 34(10):1034-42. PubMed ID: 26598744
[TBL] [Abstract][Full Text] [Related]
35. The efficacy of adjuvant trastuzumab in HER-2 positive breast cancer with axillary lymph node metastases according to the treatment duration.
Sendur MA; Aksoy S; Ozdemir NY; Yazici O; Zengin N; Altundag K
Curr Med Res Opin; 2014 Dec; 30(12):2535-42. PubMed ID: 25222762
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of taxane plus anthracycline with or without cyclophosphamide in Chinese node-positive breast cancer patients: an open-label, randomized controlled trial.
Lin Y; Wang C; Huang X; Zhou X; Zhou Y; Mao F; Guan J; Song Y; Zhong Y; Xu Y; Sun Q
Breast Cancer Res Treat; 2019 Jun; 175(3):659-666. PubMed ID: 30937656
[TBL] [Abstract][Full Text] [Related]
37. Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer.
Dieci MV; Conte P; Bisagni G; Brandes AA; Frassoldati A; Cavanna L; Musolino A; Giotta F; Rimanti A; Garrone O; Bertone E; Cagossi K; Sarti S; Ferro A; Piacentini F; Maiorana A; Orvieto E; Sanders M; Miglietta F; Balduzzi S; D'Amico R; Guarneri V
Ann Oncol; 2019 Mar; 30(3):418-423. PubMed ID: 30657852
[TBL] [Abstract][Full Text] [Related]
38. Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: a network meta-analysis.
Shen Y; Fujii T; Ueno NT; Tripathy D; Fu N; Zhou H; Ning J; Xiao L
Breast Cancer Res Treat; 2019 Jan; 173(1):1-9. PubMed ID: 30242579
[TBL] [Abstract][Full Text] [Related]
39. Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial.
Conte P; Bisagni G; Piacentini F; Sarti S; Minichillo S; Anselmi E; Aieta M; Gebbia V; Schirone A; Musolino A; Garrone O; Beano A; Rimanti A; Giotta F; Turletti A; Miglietta F; Dieci MV; Vicini R; Balduzzi S; D'Amico R; Guarneri V
J Clin Oncol; 2023 Nov; 41(32):4976-4981. PubMed ID: 37748109
[No Abstract] [Full Text] [Related]
40. Do all patients with HER2 positive breast cancer require one year of adjuvant trastuzumab? A systematic review and meta-analysis.
Stewart P; Blanchette P; Shah PS; Ye XY; Boldt RG; Fernandes R; Vandenberg T; Raphael J
Breast; 2020 Dec; 54():203-210. PubMed ID: 33130486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
